Condition: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · Recurrent B Acute Lymphoblastic Leukemia · Refractory B Acute Lymphoblastic Leukemia · Sponsor: National Cancer Institute (NCI)
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | Suspended |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | Suspended |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | Suspended |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | Suspended |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | Suspended |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | Suspended |
| Katmai Oncology Group | Anchorage, Alaska, United States | Suspended |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | Suspended |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Suspended |
| Mercy Hospital Fort Smith | Fort Smith, Arkansas, United States | Suspended |
| PCR Oncology | Arroyo Grande, California, United States | Suspended |
+ 266 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03739814